A Seventh Circuit panel on Monday refused to revive landmark private antitrust claims from Humira (adalimumab) buyers accusing pharmaceutical firm AbbVie of using a "patent thicket" to illegally shield the blockbuster immunosuppressant from competition, ruling that there's nothing wrong with AbbVie's high volume of patents, LAW360 reported. 2 August 2022
Gracell Biotechnologies, a clinical-stage biopharmaceutical company, has announced the appointment of Wendy Li , as its chief medical officer (CMO). 1 August 2022
GreenLight Biosciences has announced a collaboration with the National Institutes of Health (NIH) to develop COVID-19 vaccines that are more broadly protective against new variants and with longer-lasting effects. 1 August 2022
Vicinitas Therapeutics, a biotechnology company advancing a proprietary targeted protein stabilization platform to develop novel therapeutics in cancer and genetic disorders, has announced its launch and a $65 million Series A financing. 29 July 2022
GSK has announced that the US Food and Drug Administration (FDA) has approved Benlysta (belimumab) for the treatment of children aged five to 17 with active lupus nephritis (LN) who are receiving standard therapy. 28 July 2022
LFB, a French biopharma that develops, manufactures and markets plasma-derived products and recombinant proteins, has announced that its Cevenfacta (eptacog beta) has been granted marketing authorization in Europe. 26 July 2022
Cell and gene therapy companies Oxford Biomedica and Juno Therapeutics have expanded their research agreement to include two new viral vector programs for CAR-T cell treatments, taking the total to six. 21 July 2022
F-star Therapeutics, a clinical-stage biopharmaceutical company pioneering bispecifics in immunotherapy so more people with cancer can live longer and improved lives, today announced that it has entered into a license agreement with Japan’s Takeda. 20 July 2022
Anglo-American company Immunocore, a biotech developing a novel class of T cell receptor bispecific immunotherapies designed to treat a broad range of diseases, including cancer, autoimmune and infectious diseases, has announced a $140 million private placement financing. 19 July 2022
Israel-based Purple Biotech today announced the decision by Isaac Israel, former chief executive to step down from his CEO role and reduce the scope of his engagement with the company for personal reasons, effective July 10, 2022. 14 July 2022
Taiwan pharma OEP Group has signed an exclusive deal with ADC Therapeutics' joint venture in Shanghai - Overland ADCT - to commercialize Zynlonta (loncastuximab tesirine) in Taiwan and Singapore. 12 July 2022
ABL, a pure play contract development and manufacturing organization specialized in the development and manufacturing of virus for vaccine candidates, gene and cancer therapies, has announced a collaboration with KaliVir Immunotherapeutics. 11 July 2022
The National Institute for Health and Care Excellence (NICE) has updated its recommendation for Tremfya (guselkumab), alone or with methotrexate, as an option for treating active psoriatic arthritis (PsA) in adults whose disease has not responded well enough to disease-modifying antirheumatic drugs or who cannot tolerate them. 8 July 2022
Drug discovery firm Absci, a specialist in AI and synthetic biology, has entered into a collaboration agreement with an undisclosed biotech partner. 7 July 2022
US pharma major Bristol Myers Squibb has announced that the National Institute for Health and Care Excellence (NICE), the cost-effectiveness watchdog for England and Wales, has issued a new Final Appraisal Document (FAD) relating to Opdivo (nivolumab). 7 July 2022
C4X Discovery Holdings, a pioneering UK drug discovery company, today announced that it has received a milestone payment of 3 million euros ($3.1 million) from Sanofi under the interleukin (IL)-17A Inhibitor program license agreement entered into in April 2021. 6 July 2022
In the UK, the National Institute for Health and Care Excellence (NICE) has given a positive reimbursement decision on Leo Pharma’s IL-13 blocker Adtralza (tralokinumab). 29 June 2022
Texas, USA-based mRNA genetic medicines company ReCode Therapeutics today announced the close of a Series B extension financing round, co-led by new investors, Leaps by Bayer. 29 June 2022
The US Food and Drug Administration (FDA) has approved Breyanzi (lisocabtagene maraleucel), a CD19-directed chimeric antigen receptor (CAR) T cell therapy, from Bristol Myers Squibb, for the treatment of adult patients with large B-cell lymphoma (LBCL). 25 June 2022
Italian pharma major Recordati saw its shares rise more than 5% to 52.00 euros in early trading, as it announced a deal to expand its portfolio of marketed rare disease medicines. 4 October 2024
Paris-based asset manager Kurma Partners has raised 140 million euros ($154 million), successfully completing the first closing of Biofund IV 4 October 2024
Bristol Myers Squibb has received a new approval from the US Food and Drug Administration for its blockbuster checkpoint blocker, Opdivo (nivolumab). 4 October 2024
Singapore’s Agency for Science, Technology and Research (A*STAR) and US biotech incubator Flagship Pioneering have agree to collaborate on advancing health and sustainability outcomes in Singapore and the broader Asia Pacific region. 4 October 2024
The US Food and Drug Administration (FDA) has removed the partial clinical hold on delpacibart etedesiran (del-desiran/AOC 1001), an investigational treatment designed to address the root cause of myotonic dystrophy type 1 (DM1), under development by US biotech Avidity Biosciences . 4 October 2024
The US Food and Drug Administration (FDA) has granted the Gilead Sciences subsidiary Kite a Regenerative Medicine Advanced Therapy Designation (RMAT) for Yescarta (axicabtagene ciloleucel) for adults with newly-diagnosed, high-risk large B-cell lymphoma (LBCL). 3 October 2024
Kedrion Biopharma has finalized an agreement with Germany-based Biotest for the long-term commercialization and distribution of Yimmugo (immune globulin) in the USA. 3 October 2024
US clinical-stage biotech Arcus Biosciences has entered into a clinical trial collaboration with AstraZeneca on renal cancer treatments. 3 October 2024
PeptiDream says that its wholly-owned PDRadiopharma subsidiary has entered into a strategic partnership with French nuclear medicines firm Curium. 3 October 2024
Privately-held Ferring Pharmaceuticals has announced the opening of a global manufacturing hub in Finland for the drug substance of its intravesical non-replicating gene therapy Adstiladrin (nadofaragene firadenovec-vncg). 3 October 2024
Shares of UK drug developer Hemogenyx Pharmaceuticals rose as much as 9% and closed up 5.9% at 1.70 pence yesterday on the news of a further investment from Prevail Partners. 3 October 2024
UK-based biotech Resolution Therapeutics has announced the completion of a £63.5 million ($76.8 million) series B financing round led by Syncona. 3 October 2024
The BioIndustry Association (BIA), in collaboration with the Centre for Process Innovation (CPI), has published a new report on the UK’s mRNA sector. 2 October 2024
Aspen Neuroscience, a private biotechnology company specializing in autologous cell therapies, has announced the opening of a major new facility near its headquarters in San Diego. 2 October 2024
Privately-held UK biotech Curve Therapeutics today announced the further strengthening of its leadership team with the appointments of Andre Hoekema as chairman of the board and Cora Griffin as head of business development. 2 October 2024
NK:IO, a London startup developing a cell therapy for treating solid tumors, has announced the appointment of a permant chief executive and the finalization of a seed funding round. 2 October 2024